Page 13 - Read Online
P. 13

Miller et al. Mini-invasive Surg 2021;5:24  https://dx.doi.org/10.20517/2574-1225.2021.25  Page 5 of 12


 Table 2. Oncologic outcomes from selected studies after robot-assisted radical cystectomy

 Ref. and study acronym  Year  Surgical approach  Cases, (n) PSM, n (%) Lymph node yield, mean (SD) or median (IQR or range)  RFS  CSS  OS

 Comparative studies, randomized
 [6,7]
 RAZOR trial, multiple authors  2020, 2018 ORC  152  7 (5)  25.7 (SD 14.5)  65%, 3 yr  nr  69%, 3 yr
 RARC  150  9 (6)  23.3 (SD 12.5)                          68%, 3 yr  nr         74%, 3 yr
 [8]
 CORAL trial, Khan et al.  2020  ORC  20  2 (10)  18.5 (IQR 14-25)  60%, 5 yr  64%, 5 yr  55%, 5 yr
 RARC  20  3 (15)  14.5 (IQR 11-21)                        58%, 5 yr  68%, 5 yr  65%, 5 yr
 LRC  19  1 (5)  15.5 (IQR 12-22)                          71%, 5 yr  69%, 5 yr  61%, 5 yr
 [9]                                                                           #          #
 Bochner et al.  2018  ORC  58  3 (5)  29 (IQR 22-38)      59%, 5 yr  80%, 5 yr  65%, 5 yr
                                                                              #           #
 RARC  60  2 (3)  31 (IQR 23-37)                           64%, 5 yr  75%, 5 yr  65%, 5 yr
 [10]
 Parekh et al.  2012  ORC  20  1 (5)  23 (IQR 15-28)       nr         nr         nr
 RARC  20  1 (5)  11 (IQR 9-22)                            nr         nr         nr
 [11]
 Nix et al.  2010  ORC  20  0 (0)  18 (range 8-30)         nr         nr         nr
 RARC  21  0 (0)  19 (range 12-30)                         nr         nr         nr
 Comparative studies, non-randomized
 [12]
 RACE study, Wijburg et al.  2021  ORC  168  nr (18)*  13 (IQR 9-18)  75%, 1 yr  nr  nr
 RARC  180  nr (6)  15 (IQR 11-21)                         76%, 1 yr  nr         nr
 [13]
 Asil et al.  2021  ORC  31  1 (3)  22 (nr)                nr         nr         nr
 RARC  61  9 (15)  Range 22-25                             nr         nr         nr
 [14]                                                              #                      #
 Ip et al.  2020  ORC  159  23 (14)  20 (SD 14)*           75%, 5 yr  nr         65%, 5 yr
                                                                    #                     #
 RARC  73  8 (11)  12 (SD 8)                               80 %, 5 yr  nr        70%, 5 yr
 [15]
 Zhang et al.  2020  ORC  272  22 (8)  nr                  nr         nr         55%, 5 yr
 RARC  676  34 (5)  nr                                     nr         nr         58%, 5 yr
 [16]
 Faraj et al.  2019  ORC  278  15 (5)  12 (IQR 9-18)*      63%, 10 yr  nr        46%, 10 yr
 RARC  203  7 (3)  18 (IQR 14-24)                          70%, 10 yr  nr        40%, 10 yr
 [17]
 Moschini et al.  2019  ORC  1666  160 (10)  16 (10-24)    nr         nr         nr
 RARC  870  112 (13)  18 (12-25)                           nr         nr         nr
 [18]
 Simone et al.  2018  RARC, ICUD only  64  0 (0)  33.4 (SD 12.3)  79%, 4 yr  85%, 4 yr  82%, 4 yr
 ORC  46  0 (0)  31.3 (SD 14.6)                            73%, 4 yr  86%, 4 yr  80%, 4 yr
 [19]
 Hanna et al.  2018  ORC  7513  (10.7)  12 (IQR 7-20)*     nr         nr         nr
 RARC  2048  (9.3)  17 (IQR 10-25)                         nr         nr         nr
 [20]
 Gandagli et al.  2016  ORC  230  31 (13)  13 (IQR 9-17)   57%, 5 yr  62%, 5 yr  58%, 5 yr
 RARC  138  12 (9)  12 (IQR 8-17)                          54%, 5 yr  74%, 5 yr  59%, 5 yr
 [21]
 Tan et al.  2016  ORC  90  17 (19)*  12.6 (SD 10.9)       70%, 2 yr  81%, 2 yr  74%, 2 yr
   8   9   10   11   12   13   14   15   16   17   18